Silo Pharma Advances PTSD Treatment with FDA-Requested Safety Study
Silo Pharma is conducting a critical safety study on its intranasal PTSD treatment SPC-15, which could potentially provide a new therapeutic option for patients struggling with stress-related disorders by meeting FDA requirements for clinical advancement.
Pharmaceutical company Silo Pharma is progressing its lead therapeutic candidate SPC-15, an intranasal treatment targeting post-traumatic stress disorder (PTSD), through a crucial safety and toxicology study requested by the Food and Drug Administration (FDA).
The seven-day safety study, conducted in partnership with Frontage Laboratories, is designed to strengthen Silo Pharma's upcoming Investigational New Drug (IND) application. Developed collaboratively with Columbia University, SPC-15 is a 5-HT4 receptor agonist that could potentially qualify for the FDA's 505(b)(2) regulatory pathway.
Concurrently with the safety study, Silo Pharma is running a Good Laboratory Practice (GLP)-compliant toxicology study, maintaining its timeline for FDA submission this year. The research represents a significant step toward addressing an critical mental health need, as PTSD and stress-related disorders remain challenging to treat effectively.
The intranasal delivery method of SPC-15 could offer advantages over traditional treatment approaches, potentially providing more rapid and targeted relief for patients experiencing PTSD and stress-induced anxiety disorders. This innovative approach underscores Silo Pharma's commitment to developing novel therapeutics for underserved medical conditions.